9 results about "Polar body" patented technology

The invention provides an oocyte in-vitro maturation culture solution additive and application thereof. The additive is tert-butylhydroquinone. By adding 100 [mu] g / mL of TBHQ into a basic culture solution, the first polar body discharge rate of oocytes is remarkably increased to 77.29%, the ROS level is reduced, and the blastocyst rate of in-vitro fertilized embryos is increased. The technology is suitable for breed conservation of livestock genetic resources such as sheep and can replace live livestock transportation to reduce the cost.

The invention provides application of endothelin in oocyte in-vitro maturation and embryo in-vitro culture. New application of endothelin is found, the endothelin can improve the polar body discharge rate of oocytes matured in vitro, promote cytoplasm maturing and improve the normal arrangement proportion of organelles after maturing, certain promotion is provided for improvement of oocyte fertilization, and meanwhile subsequent blastocyst development is promoted. The invention further provides an in-vitro maturation culture solution of the sheep oocytes and an in-vitro maturation method of the sheep oocytes, the in-vitro maturation culture solution contains endothelin, and after the sheep oocytes are treated with the in-vitro maturation culture solution containing the endothelin concentration, the mitochondrial membrane potential level of the oocytes can be remarkably improved, and the survival rate of the sheep oocytes is increased. ROS (reactive oxygen species) in the oocytes is remarkably reduced, and the ATP (adenosine triphosphate) and GSH (glutathione) levels of the oocytes and the normal proportion level of spindles are improved; the maturation rate, the fertilization efficiency, the blastocyst number and the blastocyst rate are remarkably increased, in-vitro maturation of sheep oocytes and in-vitro development of early embryos are promoted, and the production efficiency of the sheep in-vitro embryos is effectively improved.

The invention discloses application of a compound shown in a formula I in promoting in-vitro cultured oocyte development or in-vitro embryo development, and in the formula I, R1 is selected from halogenated alkyl; r2 is selected from H, halogen or C1-6 alkyl; n is selected from 0, 1, 2 or 3. According to the application, the expansion area of cumulus cells in the cumulus-oocyte complex can be increased; the oxidative damage of the cumulus-oocyte complex is relieved; the first polar body discharge rate of the oocytes is improved; the abnormal distribution rate of mitochondria in oocytes is reduced; the membrane potential of mitochondria in the oocyte is improved; and the cleavage rate and blastocyst formation rate of fertilized eggs can be improved, and the apoptosis rate of oocytes can be reduced.

This invention provides a precise method for extracting cell polar bodies, belonging to the field of subcellular micromanipulation technology. The method includes the following steps: S1: Subtracting positive and negative defocused images, binarizing them, and using polar coordinate information to locate the polar body; S2: Performing force analysis on the polar body, and determining the motion trajectory of the microneedle approaching the polar body through finite element simulation modeling; S3: Inserting the microneedle into the cell, using an active disturbance rejection controller motion control algorithm to compensate for disturbances and errors during the microneedle's movement, correcting the microneedle's motion trajectory, and ensuring the microneedle approaches the polar body along the trajectory determined in S2; the microneedle then extracts the polar body. This invention manipulates cell polar bodies under a microscope while the microneedle is fixed in a suction-holding state. It allows the microneedle to be moved to a suitable position for polar body removal without staining the polar body, avoiding the difficulties caused by photobleaching and fluorescence fields resulting from staining, which can affect microneedle movement and the calculation of cytoplasm removal. It also reduces the damage to oocyte viability caused by excessive cytoplasm removal.

The invention discloses a novel application of a compound MLN4924 (Pevonedat) in preparation of a medicine for improving oocyte quality and treating related diseases, and belongs to the technical field of biological medicines. PCOS animal model experiments prove that the reproductive endocrine indexes of model animals can be remarkably improved by applying the MLN4924, and the reproductive endocrine indexes are specifically represented by restoring the regularity of an estrus cycle and reducing the levels of testosterone and luteinizing hormone in serum; meanwhile, the fertility is improved, and the birth number is increased. In the aspect of oocyte quality, the treatment can increase the number of normal oocytes in an ovary, improve the first polar body discharge rate of in-vitro maturation of the oocytes and improve the blastocyst formation rate after in-vitro fertilization. A further mechanism research shows that the MLN4924 can inhibit the plasmosis of the TRIM21 in the ovarian granular cells and down-regulate the expression level of the protein of the TRIM21. The results show that the MLN4924 provides a new drug choice for developing related diseases for treating polycystic ovarian syndrome (PCOS) and improving oocyte quality.

The application relates to an image recognition-based method for positioning an oocyte polar body in an intracytoplasmic sperm injection, obtaining a microscopic digital image of an oocyte; determining an inner edge of a zona pellucida, an outer edge of a cytoplasm and a peripheral gap region located between the two according to the microscopic digital image; extracting a candidate region in the peripheral gap region; respectively judging whether each candidate region is located in the peripheral gap region, is not connected with the cytoplasm region and is not connected with the zona pellucida outer side region; determining a valid candidate region which is located in the peripheral gap region, is not connected with the cytoplasm region and is not connected with the zona pellucida outer side region; determining a target polar body region according to the valid candidate region; determining a polar body center position and polar body orientation information according to the target polar body region, and outputting a polar body positioning result. The method can be implemented based on a microscopic digital image, and is favorable for improving the stability, consistency and automation application value of the polar body positioning result.

The application discloses a method for inducing triploid of Haliotis discus hannai Ino by salinity, comprising the following steps: (1) synchronously fertilizing sperm and ovum of Haliotis discus hannai Ino to obtain fertilized eggs; (2) when the proportion of the first polar body appearing in the fertilized eggs obtained in step (1) is 60-70%, the fertilized eggs are subjected to high-salt treatment or low-salt treatment; and (3) the fertilized eggs treated in step (2) are subjected to reperfusion treatment of salinity gradient sand-filtered seawater, so as to gradually adjust the osmotic pressure by the salinity gradient sand-filtered seawater, slow down the damage to the fertilized eggs, and then resuspend in fresh sand-filtered seawater with normal salinity, and perform conventional incubation and cultivation. The application can realize efficient induction of triploid by optimizing the salinity and reperfusion steps, avoids the problems of drug residues and equipment requirements in traditional chemical and physical methods, and has the advantages of safety, simplicity and high efficiency.